---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-012513"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:40:37.811542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AstraZeneca exercises final option to develop brensocatib in COPD/asthma

## Summary
- AstraZeneca exercised second option under 2016 license to develop brensocatib in COPD or asthma beyond Phase 2b.
- Final commercialization terms subject to good faith negotiation; no financial details disclosed.
- Insmed retains full rights to brensocatib in all other indications.
- Brensocatib is a DPP1 inhibitor for neutrophil-mediated diseases; AstraZeneca already had first option.

## SEC filing metadata
- accession: 0001140361-24-012513
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124012513/0001140361-24-012513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124012513/ef20023812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-012513
- JSON: https://secwatch.observer/filing/0001140361-24-012513.json
- Plain text: https://secwatch.observer/filing/0001140361-24-012513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.